Abstract：
Resmetirom is an oral selective THR-β agonist conditionally approved for the treatment of patients with noncirrhotic MASH with moderate to advanced fibrosis. Resmetirom restores mitochondrial and hepatic metabolic function; reduces atherogenic lipids; improves hepatic steatosis, inflammation, and fibrosis; and has no significant effect on THR-α. To view this Bench to Bedside, open or download the PDF.
摘要：
Resmetrom是一种口服选择性THR-β激动剂，有条件地批准用于治疗患有中度至晚期纤维化的非肝硬化MASH患者。Resmetrom恢复线粒体和肝脏代谢功能;减少动脉粥样硬化脂质;改善肝脏脂肪变性，炎症,和纤维化；对THR-α无明显影响。要查看此长凳到床边，打开或下载PDF。
